Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Type of study
Publication year range
3.
Klin Khir ; (5): 29-32, 2001.
Article in Russian | MEDLINE | ID: mdl-11503331

ABSTRACT

Experience of application of alprostan (PGE1, alprostadil) in 19 patients with atherosclerotic affection of vessels, chronic and acute ischemia of lower extremities in III-IV stage in combination with affection of other vascular basins was summarized. In 10 patients, to whom operative vascular reconstruction was contraindicated and/or technically unrealizable, the conservative treatment was conducted using alprostan during 12-25 days up to the clinical effect achievement (total dose up to 1.6 mg). In 9 patients after performance of conservative treatment using alprostan the vascular bed reconstruction was done. Daily infusion of alprostan in 0.1 mg dose diluted in 250-400 ml of isotonic solution of sodium chloride during 2.5-3 h with duration of course not less than 15 days and 1.2-2.2 mg total dose of preparation constitutes an optimal scheme of treatment. Good result was noted in treatment of patients in stage II of ischemia, application of alprostan in stage IV of ischemia had permitted to reduce the extremity amputation volume or to escape it on the whole, and to restore more rapidly the cutaneous integrity in the trophic disorders regions. The alprostan usage is trustworthy in patients with multifocal atherosclerosis with the cardiac coronary vessels affection in an ischemic heart disease.


Subject(s)
Alprostadil/therapeutic use , Arteriosclerosis Obliterans/drug therapy , Arteriosclerosis Obliterans/pathology , Fibrinolytic Agents/therapeutic use , Leg/pathology , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged
4.
Klin Khir ; (9): 12-4, 2001 Sep.
Article in Russian | MEDLINE | ID: mdl-11785391

ABSTRACT

Results of treatment of 114 patients for ten-year period, operated on for diseases of extracranial vessels, were adduced. Up to 1998 after performance of reconstructive operation as anticoagulant heparin was used in 80 patients and in last time--low-molecular heparin clexane in 34. After operation all patients survived. An ischemic insult occurred in 2-3 days after the operation in 2(2.5%) patients, while application of heparin, in 5--positive changes of the disease course were absent, in 19(23.75%)--postoperative hemorrhagic complications occurred. When clexane was administered in 2(5.9%) patients the cerebral hemodynamics improvement was not noted, complications in the early and late postoperative periods were absent. In term of observation up to 5 years good results was noted in 21(62.3%) patient, fair--in 9 (27.2%). In late postoperative period the brain hemodynamics improvement was not noted in 2 (5.9%) patients. Application of clexane for the arterial thrombosis prophylaxis is clinically substantiated and permits to reduce significantly the risk of the complications occurrence, which are observed with usage of heparin.


Subject(s)
Anticoagulants/therapeutic use , Aortic Arch Syndromes/surgery , Cardiovascular Surgical Procedures/methods , Carotid Artery Thrombosis/prevention & control , Enoxaparin/therapeutic use , Anticoagulants/administration & dosage , Enoxaparin/administration & dosage , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...